nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfuzosin—CYP3A4—prostate cancer	0.238	1	CbGaD
Alfuzosin—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0762	0.207	CbGbCtD
Alfuzosin—ADRA1B—vas deferens—prostate cancer	0.0423	0.584	CbGeAlD
Alfuzosin—CYP3A4—Bicalutamide—prostate cancer	0.04	0.109	CbGbCtD
Alfuzosin—CYP3A4—Estramustine—prostate cancer	0.0372	0.101	CbGbCtD
Alfuzosin—CYP3A4—Flutamide—prostate cancer	0.0331	0.09	CbGbCtD
Alfuzosin—CYP3A4—Abiraterone—prostate cancer	0.0331	0.09	CbGbCtD
Alfuzosin—CYP3A4—Cabazitaxel—prostate cancer	0.0245	0.0666	CbGbCtD
Alfuzosin—CYP3A4—Estrone—prostate cancer	0.024	0.0651	CbGbCtD
Alfuzosin—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0214	0.058	CbGbCtD
Alfuzosin—CYP3A4—Conjugated Estrogens—prostate cancer	0.0157	0.0426	CbGbCtD
Alfuzosin—CYP3A4—Mitoxantrone—prostate cancer	0.0143	0.0387	CbGbCtD
Alfuzosin—CYP3A4—Estradiol—prostate cancer	0.0138	0.0374	CbGbCtD
Alfuzosin—CYP3A4—Prednisone—prostate cancer	0.0118	0.0321	CbGbCtD
Alfuzosin—CYP3A4—Etoposide—prostate cancer	0.00899	0.0244	CbGbCtD
Alfuzosin—CYP3A4—Docetaxel—prostate cancer	0.00822	0.0223	CbGbCtD
Alfuzosin—CYP3A4—Doxorubicin—prostate cancer	0.00613	0.0166	CbGbCtD
Alfuzosin—ADRA1D—prostate gland—prostate cancer	0.00369	0.051	CbGeAlD
Alfuzosin—CYP3A4—urine—prostate cancer	0.00353	0.0488	CbGeAlD
Alfuzosin—ADRA1D—epithelium—prostate cancer	0.00271	0.0375	CbGeAlD
Alfuzosin—ADRA1B—renal system—prostate cancer	0.00257	0.0355	CbGeAlD
Alfuzosin—ADRA1D—urethra—prostate cancer	0.00247	0.0341	CbGeAlD
Alfuzosin—ADRA1A—prostate gland—prostate cancer	0.00212	0.0293	CbGeAlD
Alfuzosin—KCNH2—prostate gland—prostate cancer	0.00205	0.0283	CbGeAlD
Alfuzosin—KCNH2—seminal vesicle—prostate cancer	0.00173	0.0239	CbGeAlD
Alfuzosin—Prazosin—SLC22A3—prostate cancer	0.00166	0.394	CrCbGaD
Alfuzosin—ADRA1A—epithelium—prostate cancer	0.00156	0.0215	CbGeAlD
Alfuzosin—ADRA1A—renal system—prostate cancer	0.00144	0.02	CbGeAlD
Alfuzosin—KCNH2—renal system—prostate cancer	0.0014	0.0193	CbGeAlD
Alfuzosin—KCNH2—urethra—prostate cancer	0.00137	0.0189	CbGeAlD
Alfuzosin—Prazosin—SLC22A1—prostate cancer	0.00119	0.283	CrCbGaD
Alfuzosin—KCNH2—bone marrow—prostate cancer	0.00106	0.0146	CbGeAlD
Alfuzosin—KCNH2—testis—prostate cancer	0.000902	0.0125	CbGeAlD
Alfuzosin—CYP3A4—renal system—prostate cancer	0.000865	0.0119	CbGeAlD
Alfuzosin—Doxazosin—CYP2C19—prostate cancer	0.000709	0.169	CrCbGaD
Alfuzosin—KCNH2—lymph node—prostate cancer	0.000654	0.00903	CbGeAlD
Alfuzosin—Prazosin—CYP1A1—prostate cancer	0.000651	0.155	CrCbGaD
Alfuzosin—Infestation—Epirubicin—prostate cancer	0.000111	0.000452	CcSEcCtD
Alfuzosin—Drowsiness—Epirubicin—prostate cancer	0.000111	0.000452	CcSEcCtD
Alfuzosin—Bronchitis—Doxorubicin—prostate cancer	0.000111	0.000451	CcSEcCtD
Alfuzosin—Palpitations—Capecitabine—prostate cancer	0.00011	0.000448	CcSEcCtD
Alfuzosin—Arthralgia—Docetaxel—prostate cancer	0.00011	0.000446	CcSEcCtD
Alfuzosin—Chest pain—Docetaxel—prostate cancer	0.00011	0.000446	CcSEcCtD
Alfuzosin—Loss of consciousness—Capecitabine—prostate cancer	0.00011	0.000446	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Etoposide—prostate cancer	0.000109	0.000444	CcSEcCtD
Alfuzosin—Asthenia—Mitoxantrone—prostate cancer	0.000109	0.000444	CcSEcCtD
Alfuzosin—Fatigue—Etoposide—prostate cancer	0.000109	0.000443	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Epirubicin—prostate cancer	0.000109	0.000443	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000109	0.000443	CcSEcCtD
Alfuzosin—Jaundice—Epirubicin—prostate cancer	0.000109	0.000441	CcSEcCtD
Alfuzosin—Pain—Etoposide—prostate cancer	0.000108	0.00044	CcSEcCtD
Alfuzosin—Constipation—Etoposide—prostate cancer	0.000108	0.00044	CcSEcCtD
Alfuzosin—Dizziness—Estradiol—prostate cancer	0.000108	0.000439	CcSEcCtD
Alfuzosin—Dry mouth—Docetaxel—prostate cancer	0.000107	0.000436	CcSEcCtD
Alfuzosin—Upper respiratory tract infection—Doxorubicin—prostate cancer	0.000107	0.000436	CcSEcCtD
Alfuzosin—Sweating—Epirubicin—prostate cancer	0.000107	0.000433	CcSEcCtD
Alfuzosin—Arthralgia—Capecitabine—prostate cancer	0.000106	0.000432	CcSEcCtD
Alfuzosin—Chest pain—Capecitabine—prostate cancer	0.000106	0.000432	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000106	0.000429	CcSEcCtD
Alfuzosin—Hepatobiliary disease—Epirubicin—prostate cancer	0.000105	0.000428	CcSEcCtD
Alfuzosin—Oedema—Docetaxel—prostate cancer	0.000105	0.000427	CcSEcCtD
Alfuzosin—Discomfort—Capecitabine—prostate cancer	0.000105	0.000427	CcSEcCtD
Alfuzosin—Infection—Docetaxel—prostate cancer	0.000105	0.000425	CcSEcCtD
Alfuzosin—Sinusitis—Epirubicin—prostate cancer	0.000105	0.000424	CcSEcCtD
Alfuzosin—Feeling abnormal—Etoposide—prostate cancer	0.000104	0.000424	CcSEcCtD
Alfuzosin—Diarrhoea—Mitoxantrone—prostate cancer	0.000104	0.000423	CcSEcCtD
Alfuzosin—Dry mouth—Capecitabine—prostate cancer	0.000104	0.000422	CcSEcCtD
Alfuzosin—Vomiting—Estradiol—prostate cancer	0.000104	0.000422	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Etoposide—prostate cancer	0.000104	0.000421	CcSEcCtD
Alfuzosin—Shock—Docetaxel—prostate cancer	0.000104	0.000421	CcSEcCtD
Alfuzosin—Nervous system disorder—Docetaxel—prostate cancer	0.000103	0.000419	CcSEcCtD
Alfuzosin—Ill-defined disorder—Prednisone—prostate cancer	0.000103	0.000419	CcSEcCtD
Alfuzosin—Thrombocytopenia—Docetaxel—prostate cancer	0.000103	0.000419	CcSEcCtD
Alfuzosin—Rash—Estradiol—prostate cancer	0.000103	0.000418	CcSEcCtD
Alfuzosin—Infestation—Doxorubicin—prostate cancer	0.000103	0.000418	CcSEcCtD
Alfuzosin—Drowsiness—Doxorubicin—prostate cancer	0.000103	0.000418	CcSEcCtD
Alfuzosin—Infestation NOS—Doxorubicin—prostate cancer	0.000103	0.000418	CcSEcCtD
Alfuzosin—Dermatitis—Estradiol—prostate cancer	0.000103	0.000418	CcSEcCtD
Alfuzosin—Tachycardia—Docetaxel—prostate cancer	0.000103	0.000417	CcSEcCtD
Alfuzosin—Headache—Estradiol—prostate cancer	0.000102	0.000416	CcSEcCtD
Alfuzosin—Skin disorder—Docetaxel—prostate cancer	0.000102	0.000415	CcSEcCtD
Alfuzosin—Oedema—Capecitabine—prostate cancer	0.000102	0.000414	CcSEcCtD
Alfuzosin—Angioedema—Prednisone—prostate cancer	0.000102	0.000413	CcSEcCtD
Alfuzosin—Infection—Capecitabine—prostate cancer	0.000101	0.000411	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Doxorubicin—prostate cancer	0.000101	0.00041	CcSEcCtD
Alfuzosin—Urticaria—Etoposide—prostate cancer	0.000101	0.000409	CcSEcCtD
Alfuzosin—Jaundice—Doxorubicin—prostate cancer	0.0001	0.000408	CcSEcCtD
Alfuzosin—Malaise—Prednisone—prostate cancer	0.0001	0.000407	CcSEcCtD
Alfuzosin—Shock—Capecitabine—prostate cancer	0.0001	0.000407	CcSEcCtD
Alfuzosin—Rhinitis—Epirubicin—prostate cancer	0.0001	0.000407	CcSEcCtD
Alfuzosin—Abdominal pain—Etoposide—prostate cancer	0.0001	0.000407	CcSEcCtD
Alfuzosin—Nervous system disorder—Capecitabine—prostate cancer	0.0001	0.000406	CcSEcCtD
Alfuzosin—Vertigo—Prednisone—prostate cancer	0.0001	0.000406	CcSEcCtD
Alfuzosin—Thrombocytopenia—Capecitabine—prostate cancer	9.99e-05	0.000405	CcSEcCtD
Alfuzosin—Syncope—Prednisone—prostate cancer	9.98e-05	0.000405	CcSEcCtD
Alfuzosin—Tachycardia—Capecitabine—prostate cancer	9.96e-05	0.000404	CcSEcCtD
Alfuzosin—Pharyngitis—Epirubicin—prostate cancer	9.93e-05	0.000403	CcSEcCtD
Alfuzosin—Skin disorder—Capecitabine—prostate cancer	9.91e-05	0.000402	CcSEcCtD
Alfuzosin—Sweating—Doxorubicin—prostate cancer	9.88e-05	0.000401	CcSEcCtD
Alfuzosin—Urinary tract disorder—Epirubicin—prostate cancer	9.88e-05	0.000401	CcSEcCtD
Alfuzosin—Hyperhidrosis—Capecitabine—prostate cancer	9.86e-05	0.0004	CcSEcCtD
Alfuzosin—Hypotension—Docetaxel—prostate cancer	9.84e-05	0.000399	CcSEcCtD
Alfuzosin—Connective tissue disorder—Epirubicin—prostate cancer	9.83e-05	0.000399	CcSEcCtD
Alfuzosin—Urethral disorder—Epirubicin—prostate cancer	9.8e-05	0.000398	CcSEcCtD
Alfuzosin—Loss of consciousness—Prednisone—prostate cancer	9.79e-05	0.000397	CcSEcCtD
Alfuzosin—Hepatobiliary disease—Doxorubicin—prostate cancer	9.75e-05	0.000396	CcSEcCtD
Alfuzosin—Nausea—Estradiol—prostate cancer	9.72e-05	0.000394	CcSEcCtD
Alfuzosin—Vomiting—Mitoxantrone—prostate cancer	9.69e-05	0.000393	CcSEcCtD
Alfuzosin—Sinusitis—Doxorubicin—prostate cancer	9.67e-05	0.000392	CcSEcCtD
Alfuzosin—Rash—Mitoxantrone—prostate cancer	9.61e-05	0.00039	CcSEcCtD
Alfuzosin—Dermatitis—Mitoxantrone—prostate cancer	9.6e-05	0.00039	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Docetaxel—prostate cancer	9.6e-05	0.000389	CcSEcCtD
Alfuzosin—Headache—Mitoxantrone—prostate cancer	9.55e-05	0.000387	CcSEcCtD
Alfuzosin—Hypotension—Capecitabine—prostate cancer	9.53e-05	0.000387	CcSEcCtD
Alfuzosin—Arthralgia—Prednisone—prostate cancer	9.48e-05	0.000385	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	9.41e-05	0.000382	CcSEcCtD
Alfuzosin—Somnolence—Docetaxel—prostate cancer	9.37e-05	0.00038	CcSEcCtD
Alfuzosin—Discomfort—Prednisone—prostate cancer	9.36e-05	0.00038	CcSEcCtD
Alfuzosin—Eye disorder—Epirubicin—prostate cancer	9.35e-05	0.000379	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Capecitabine—prostate cancer	9.29e-05	0.000377	CcSEcCtD
Alfuzosin—Flushing—Epirubicin—prostate cancer	9.28e-05	0.000377	CcSEcCtD
Alfuzosin—Cardiac disorder—Epirubicin—prostate cancer	9.28e-05	0.000377	CcSEcCtD
Alfuzosin—Rhinitis—Doxorubicin—prostate cancer	9.28e-05	0.000376	CcSEcCtD
Alfuzosin—Dyspepsia—Docetaxel—prostate cancer	9.27e-05	0.000376	CcSEcCtD
Alfuzosin—Pharyngitis—Doxorubicin—prostate cancer	9.19e-05	0.000373	CcSEcCtD
Alfuzosin—Urinary tract disorder—Doxorubicin—prostate cancer	9.14e-05	0.000371	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Docetaxel—prostate cancer	9.1e-05	0.000369	CcSEcCtD
Alfuzosin—Asthenia—Etoposide—prostate cancer	9.1e-05	0.000369	CcSEcCtD
Alfuzosin—Connective tissue disorder—Doxorubicin—prostate cancer	9.09e-05	0.000369	CcSEcCtD
Alfuzosin—Oedema—Prednisone—prostate cancer	9.09e-05	0.000369	CcSEcCtD
Alfuzosin—Fatigue—Docetaxel—prostate cancer	9.08e-05	0.000369	CcSEcCtD
Alfuzosin—Angiopathy—Epirubicin—prostate cancer	9.07e-05	0.000368	CcSEcCtD
Alfuzosin—Urethral disorder—Doxorubicin—prostate cancer	9.07e-05	0.000368	CcSEcCtD
Alfuzosin—Nausea—Mitoxantrone—prostate cancer	9.05e-05	0.000367	CcSEcCtD
Alfuzosin—Infection—Prednisone—prostate cancer	9.03e-05	0.000366	CcSEcCtD
Alfuzosin—Mediastinal disorder—Epirubicin—prostate cancer	9.01e-05	0.000366	CcSEcCtD
Alfuzosin—Pain—Docetaxel—prostate cancer	9.01e-05	0.000366	CcSEcCtD
Alfuzosin—Constipation—Docetaxel—prostate cancer	9.01e-05	0.000366	CcSEcCtD
Alfuzosin—Dyspepsia—Capecitabine—prostate cancer	8.98e-05	0.000364	CcSEcCtD
Alfuzosin—Pruritus—Etoposide—prostate cancer	8.97e-05	0.000364	CcSEcCtD
Alfuzosin—Shock—Prednisone—prostate cancer	8.94e-05	0.000363	CcSEcCtD
Alfuzosin—Nervous system disorder—Prednisone—prostate cancer	8.91e-05	0.000362	CcSEcCtD
Alfuzosin—Tachycardia—Prednisone—prostate cancer	8.87e-05	0.00036	CcSEcCtD
Alfuzosin—Skin disorder—Prednisone—prostate cancer	8.83e-05	0.000358	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Capecitabine—prostate cancer	8.81e-05	0.000357	CcSEcCtD
Alfuzosin—Fatigue—Capecitabine—prostate cancer	8.79e-05	0.000357	CcSEcCtD
Alfuzosin—Hyperhidrosis—Prednisone—prostate cancer	8.78e-05	0.000356	CcSEcCtD
Alfuzosin—Mental disorder—Epirubicin—prostate cancer	8.76e-05	0.000356	CcSEcCtD
Alfuzosin—Pain—Capecitabine—prostate cancer	8.72e-05	0.000354	CcSEcCtD
Alfuzosin—Constipation—Capecitabine—prostate cancer	8.72e-05	0.000354	CcSEcCtD
Alfuzosin—Feeling abnormal—Docetaxel—prostate cancer	8.68e-05	0.000352	CcSEcCtD
Alfuzosin—Diarrhoea—Etoposide—prostate cancer	8.67e-05	0.000352	CcSEcCtD
Alfuzosin—Eye disorder—Doxorubicin—prostate cancer	8.65e-05	0.000351	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Docetaxel—prostate cancer	8.62e-05	0.00035	CcSEcCtD
Alfuzosin—Cardiac disorder—Doxorubicin—prostate cancer	8.59e-05	0.000348	CcSEcCtD
Alfuzosin—Flushing—Doxorubicin—prostate cancer	8.59e-05	0.000348	CcSEcCtD
Alfuzosin—Back pain—Epirubicin—prostate cancer	8.42e-05	0.000342	CcSEcCtD
Alfuzosin—Feeling abnormal—Capecitabine—prostate cancer	8.41e-05	0.000341	CcSEcCtD
Alfuzosin—Angiopathy—Doxorubicin—prostate cancer	8.4e-05	0.000341	CcSEcCtD
Alfuzosin—Dizziness—Etoposide—prostate cancer	8.38e-05	0.00034	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Capecitabine—prostate cancer	8.34e-05	0.000338	CcSEcCtD
Alfuzosin—Mediastinal disorder—Doxorubicin—prostate cancer	8.34e-05	0.000338	CcSEcCtD
Alfuzosin—Abdominal pain—Docetaxel—prostate cancer	8.33e-05	0.000338	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Prednisone—prostate cancer	8.28e-05	0.000336	CcSEcCtD
Alfuzosin—Mental disorder—Doxorubicin—prostate cancer	8.11e-05	0.000329	CcSEcCtD
Alfuzosin—Urticaria—Capecitabine—prostate cancer	8.1e-05	0.000329	CcSEcCtD
Alfuzosin—Ill-defined disorder—Epirubicin—prostate cancer	8.08e-05	0.000328	CcSEcCtD
Alfuzosin—Abdominal pain—Capecitabine—prostate cancer	8.06e-05	0.000327	CcSEcCtD
Alfuzosin—Vomiting—Etoposide—prostate cancer	8.06e-05	0.000327	CcSEcCtD
Alfuzosin—Dyspepsia—Prednisone—prostate cancer	8e-05	0.000324	CcSEcCtD
Alfuzosin—Rash—Etoposide—prostate cancer	7.99e-05	0.000324	CcSEcCtD
Alfuzosin—Dermatitis—Etoposide—prostate cancer	7.99e-05	0.000324	CcSEcCtD
Alfuzosin—Headache—Etoposide—prostate cancer	7.94e-05	0.000322	CcSEcCtD
Alfuzosin—Malaise—Epirubicin—prostate cancer	7.85e-05	0.000319	CcSEcCtD
Alfuzosin—Fatigue—Prednisone—prostate cancer	7.83e-05	0.000318	CcSEcCtD
Alfuzosin—Vertigo—Epirubicin—prostate cancer	7.82e-05	0.000317	CcSEcCtD
Alfuzosin—Syncope—Epirubicin—prostate cancer	7.81e-05	0.000317	CcSEcCtD
Alfuzosin—Back pain—Doxorubicin—prostate cancer	7.79e-05	0.000316	CcSEcCtD
Alfuzosin—Constipation—Prednisone—prostate cancer	7.77e-05	0.000315	CcSEcCtD
Alfuzosin—Palpitations—Epirubicin—prostate cancer	7.69e-05	0.000312	CcSEcCtD
Alfuzosin—Loss of consciousness—Epirubicin—prostate cancer	7.65e-05	0.00031	CcSEcCtD
Alfuzosin—Asthenia—Docetaxel—prostate cancer	7.56e-05	0.000307	CcSEcCtD
Alfuzosin—Nausea—Etoposide—prostate cancer	7.53e-05	0.000306	CcSEcCtD
Alfuzosin—Feeling abnormal—Prednisone—prostate cancer	7.49e-05	0.000304	CcSEcCtD
Alfuzosin—Ill-defined disorder—Doxorubicin—prostate cancer	7.48e-05	0.000303	CcSEcCtD
Alfuzosin—Pruritus—Docetaxel—prostate cancer	7.45e-05	0.000302	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Prednisone—prostate cancer	7.43e-05	0.000301	CcSEcCtD
Alfuzosin—Arthralgia—Epirubicin—prostate cancer	7.41e-05	0.000301	CcSEcCtD
Alfuzosin—Chest pain—Epirubicin—prostate cancer	7.41e-05	0.000301	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	7.36e-05	0.000299	CcSEcCtD
Alfuzosin—Discomfort—Epirubicin—prostate cancer	7.32e-05	0.000297	CcSEcCtD
Alfuzosin—Asthenia—Capecitabine—prostate cancer	7.32e-05	0.000297	CcSEcCtD
Alfuzosin—Malaise—Doxorubicin—prostate cancer	7.27e-05	0.000295	CcSEcCtD
Alfuzosin—Dry mouth—Epirubicin—prostate cancer	7.25e-05	0.000294	CcSEcCtD
Alfuzosin—Vertigo—Doxorubicin—prostate cancer	7.24e-05	0.000294	CcSEcCtD
Alfuzosin—Syncope—Doxorubicin—prostate cancer	7.22e-05	0.000293	CcSEcCtD
Alfuzosin—Urticaria—Prednisone—prostate cancer	7.22e-05	0.000293	CcSEcCtD
Alfuzosin—Pruritus—Capecitabine—prostate cancer	7.22e-05	0.000293	CcSEcCtD
Alfuzosin—Diarrhoea—Docetaxel—prostate cancer	7.21e-05	0.000292	CcSEcCtD
Alfuzosin—Abdominal pain—Prednisone—prostate cancer	7.18e-05	0.000291	CcSEcCtD
Alfuzosin—Palpitations—Doxorubicin—prostate cancer	7.12e-05	0.000289	CcSEcCtD
Alfuzosin—Oedema—Epirubicin—prostate cancer	7.11e-05	0.000288	CcSEcCtD
Alfuzosin—Loss of consciousness—Doxorubicin—prostate cancer	7.08e-05	0.000287	CcSEcCtD
Alfuzosin—Infection—Epirubicin—prostate cancer	7.06e-05	0.000286	CcSEcCtD
Alfuzosin—Shock—Epirubicin—prostate cancer	6.99e-05	0.000284	CcSEcCtD
Alfuzosin—Diarrhoea—Capecitabine—prostate cancer	6.98e-05	0.000283	CcSEcCtD
Alfuzosin—Nervous system disorder—Epirubicin—prostate cancer	6.97e-05	0.000283	CcSEcCtD
Alfuzosin—Dizziness—Docetaxel—prostate cancer	6.97e-05	0.000283	CcSEcCtD
Alfuzosin—Thrombocytopenia—Epirubicin—prostate cancer	6.96e-05	0.000282	CcSEcCtD
Alfuzosin—Tachycardia—Epirubicin—prostate cancer	6.94e-05	0.000281	CcSEcCtD
Alfuzosin—Skin disorder—Epirubicin—prostate cancer	6.9e-05	0.00028	CcSEcCtD
Alfuzosin—Hyperhidrosis—Epirubicin—prostate cancer	6.87e-05	0.000279	CcSEcCtD
Alfuzosin—Chest pain—Doxorubicin—prostate cancer	6.86e-05	0.000278	CcSEcCtD
Alfuzosin—Arthralgia—Doxorubicin—prostate cancer	6.86e-05	0.000278	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	6.81e-05	0.000276	CcSEcCtD
Alfuzosin—Discomfort—Doxorubicin—prostate cancer	6.78e-05	0.000275	CcSEcCtD
Alfuzosin—Dizziness—Capecitabine—prostate cancer	6.75e-05	0.000274	CcSEcCtD
Alfuzosin—Dry mouth—Doxorubicin—prostate cancer	6.71e-05	0.000272	CcSEcCtD
Alfuzosin—Vomiting—Docetaxel—prostate cancer	6.7e-05	0.000272	CcSEcCtD
Alfuzosin—Rash—Docetaxel—prostate cancer	6.64e-05	0.00027	CcSEcCtD
Alfuzosin—Hypotension—Epirubicin—prostate cancer	6.64e-05	0.000269	CcSEcCtD
Alfuzosin—Dermatitis—Docetaxel—prostate cancer	6.64e-05	0.000269	CcSEcCtD
Alfuzosin—Headache—Docetaxel—prostate cancer	6.6e-05	0.000268	CcSEcCtD
Alfuzosin—Oedema—Doxorubicin—prostate cancer	6.58e-05	0.000267	CcSEcCtD
Alfuzosin—Infection—Doxorubicin—prostate cancer	6.53e-05	0.000265	CcSEcCtD
Alfuzosin—Asthenia—Prednisone—prostate cancer	6.52e-05	0.000264	CcSEcCtD
Alfuzosin—Vomiting—Capecitabine—prostate cancer	6.49e-05	0.000263	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Epirubicin—prostate cancer	6.47e-05	0.000263	CcSEcCtD
Alfuzosin—Shock—Doxorubicin—prostate cancer	6.47e-05	0.000262	CcSEcCtD
Alfuzosin—Nervous system disorder—Doxorubicin—prostate cancer	6.45e-05	0.000262	CcSEcCtD
Alfuzosin—Thrombocytopenia—Doxorubicin—prostate cancer	6.44e-05	0.000261	CcSEcCtD
Alfuzosin—Rash—Capecitabine—prostate cancer	6.43e-05	0.000261	CcSEcCtD
Alfuzosin—Pruritus—Prednisone—prostate cancer	6.43e-05	0.000261	CcSEcCtD
Alfuzosin—Dermatitis—Capecitabine—prostate cancer	6.43e-05	0.000261	CcSEcCtD
Alfuzosin—Tachycardia—Doxorubicin—prostate cancer	6.42e-05	0.00026	CcSEcCtD
Alfuzosin—Headache—Capecitabine—prostate cancer	6.39e-05	0.000259	CcSEcCtD
Alfuzosin—Skin disorder—Doxorubicin—prostate cancer	6.39e-05	0.000259	CcSEcCtD
Alfuzosin—Hyperhidrosis—Doxorubicin—prostate cancer	6.36e-05	0.000258	CcSEcCtD
Alfuzosin—Somnolence—Epirubicin—prostate cancer	6.32e-05	0.000256	CcSEcCtD
Alfuzosin—Nausea—Docetaxel—prostate cancer	6.26e-05	0.000254	CcSEcCtD
Alfuzosin—Dyspepsia—Epirubicin—prostate cancer	6.26e-05	0.000254	CcSEcCtD
Alfuzosin—Diarrhoea—Prednisone—prostate cancer	6.22e-05	0.000252	CcSEcCtD
Alfuzosin—Hypotension—Doxorubicin—prostate cancer	6.14e-05	0.000249	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Epirubicin—prostate cancer	6.14e-05	0.000249	CcSEcCtD
Alfuzosin—Fatigue—Epirubicin—prostate cancer	6.13e-05	0.000249	CcSEcCtD
Alfuzosin—Pain—Epirubicin—prostate cancer	6.08e-05	0.000247	CcSEcCtD
Alfuzosin—Constipation—Epirubicin—prostate cancer	6.08e-05	0.000247	CcSEcCtD
Alfuzosin—Nausea—Capecitabine—prostate cancer	6.06e-05	0.000246	CcSEcCtD
Alfuzosin—Dizziness—Prednisone—prostate cancer	6.01e-05	0.000244	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Doxorubicin—prostate cancer	5.99e-05	0.000243	CcSEcCtD
Alfuzosin—Feeling abnormal—Epirubicin—prostate cancer	5.86e-05	0.000238	CcSEcCtD
Alfuzosin—Somnolence—Doxorubicin—prostate cancer	5.85e-05	0.000237	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Epirubicin—prostate cancer	5.81e-05	0.000236	CcSEcCtD
Alfuzosin—Dyspepsia—Doxorubicin—prostate cancer	5.79e-05	0.000235	CcSEcCtD
Alfuzosin—Vomiting—Prednisone—prostate cancer	5.78e-05	0.000234	CcSEcCtD
Alfuzosin—Rash—Prednisone—prostate cancer	5.73e-05	0.000232	CcSEcCtD
Alfuzosin—Dermatitis—Prednisone—prostate cancer	5.72e-05	0.000232	CcSEcCtD
Alfuzosin—Headache—Prednisone—prostate cancer	5.69e-05	0.000231	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Doxorubicin—prostate cancer	5.68e-05	0.00023	CcSEcCtD
Alfuzosin—Fatigue—Doxorubicin—prostate cancer	5.67e-05	0.00023	CcSEcCtD
Alfuzosin—Urticaria—Epirubicin—prostate cancer	5.65e-05	0.000229	CcSEcCtD
Alfuzosin—Constipation—Doxorubicin—prostate cancer	5.62e-05	0.000228	CcSEcCtD
Alfuzosin—Pain—Doxorubicin—prostate cancer	5.62e-05	0.000228	CcSEcCtD
Alfuzosin—Abdominal pain—Epirubicin—prostate cancer	5.62e-05	0.000228	CcSEcCtD
Alfuzosin—Feeling abnormal—Doxorubicin—prostate cancer	5.42e-05	0.00022	CcSEcCtD
Alfuzosin—Nausea—Prednisone—prostate cancer	5.4e-05	0.000219	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Doxorubicin—prostate cancer	5.38e-05	0.000218	CcSEcCtD
Alfuzosin—Urticaria—Doxorubicin—prostate cancer	5.22e-05	0.000212	CcSEcCtD
Alfuzosin—Abdominal pain—Doxorubicin—prostate cancer	5.2e-05	0.000211	CcSEcCtD
Alfuzosin—Asthenia—Epirubicin—prostate cancer	5.1e-05	0.000207	CcSEcCtD
Alfuzosin—Pruritus—Epirubicin—prostate cancer	5.03e-05	0.000204	CcSEcCtD
Alfuzosin—Diarrhoea—Epirubicin—prostate cancer	4.86e-05	0.000197	CcSEcCtD
Alfuzosin—Asthenia—Doxorubicin—prostate cancer	4.72e-05	0.000191	CcSEcCtD
Alfuzosin—Dizziness—Epirubicin—prostate cancer	4.7e-05	0.000191	CcSEcCtD
Alfuzosin—Pruritus—Doxorubicin—prostate cancer	4.65e-05	0.000189	CcSEcCtD
Alfuzosin—Vomiting—Epirubicin—prostate cancer	4.52e-05	0.000183	CcSEcCtD
Alfuzosin—Diarrhoea—Doxorubicin—prostate cancer	4.5e-05	0.000183	CcSEcCtD
Alfuzosin—Rash—Epirubicin—prostate cancer	4.48e-05	0.000182	CcSEcCtD
Alfuzosin—Dermatitis—Epirubicin—prostate cancer	4.48e-05	0.000182	CcSEcCtD
Alfuzosin—Headache—Epirubicin—prostate cancer	4.45e-05	0.000181	CcSEcCtD
Alfuzosin—Dizziness—Doxorubicin—prostate cancer	4.35e-05	0.000176	CcSEcCtD
Alfuzosin—Nausea—Epirubicin—prostate cancer	4.22e-05	0.000171	CcSEcCtD
Alfuzosin—Vomiting—Doxorubicin—prostate cancer	4.18e-05	0.00017	CcSEcCtD
Alfuzosin—Rash—Doxorubicin—prostate cancer	4.15e-05	0.000168	CcSEcCtD
Alfuzosin—Dermatitis—Doxorubicin—prostate cancer	4.14e-05	0.000168	CcSEcCtD
Alfuzosin—Headache—Doxorubicin—prostate cancer	4.12e-05	0.000167	CcSEcCtD
Alfuzosin—Nausea—Doxorubicin—prostate cancer	3.91e-05	0.000158	CcSEcCtD
Alfuzosin—ADRA1A—Signaling Pathways—FGF10—prostate cancer	9.48e-06	0.000135	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—HIF1A—prostate cancer	9.47e-06	0.000135	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—JAK2—prostate cancer	9.46e-06	0.000134	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ADRB2—prostate cancer	9.38e-06	0.000133	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—TCN2—prostate cancer	9.34e-06	0.000133	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTA3—prostate cancer	9.34e-06	0.000133	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—UCP3—prostate cancer	9.34e-06	0.000133	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PDHA1—prostate cancer	9.34e-06	0.000133	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—JAK2—prostate cancer	9.25e-06	0.000131	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—LEP—prostate cancer	9.25e-06	0.000131	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—MAP2K1—prostate cancer	9.22e-06	0.000131	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CAV1—prostate cancer	9.16e-06	0.00013	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—LPL—prostate cancer	9.16e-06	0.00013	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3CD—prostate cancer	9.16e-06	0.00013	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—VAV3—prostate cancer	9.15e-06	0.00013	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—IL2—prostate cancer	9.09e-06	0.000129	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PDGFRB—prostate cancer	9.08e-06	0.000129	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—KDR—prostate cancer	9.06e-06	0.000129	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TGFBR2—prostate cancer	9.02e-06	0.000128	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PIK3CB—prostate cancer	8.99e-06	0.000128	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HSD3B1—prostate cancer	8.91e-06	0.000127	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SLC22A3—prostate cancer	8.91e-06	0.000127	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ITPR1—prostate cancer	8.87e-06	0.000126	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ITGB3—prostate cancer	8.84e-06	0.000126	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—ESR1—prostate cancer	8.83e-06	0.000125	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PIK3CB—prostate cancer	8.79e-06	0.000125	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CXCL8—prostate cancer	8.64e-06	0.000123	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—BAD—prostate cancer	8.62e-06	0.000122	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ERBB3—prostate cancer	8.58e-06	0.000122	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—FGFR2—prostate cancer	8.57e-06	0.000122	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTA4—prostate cancer	8.54e-06	0.000121	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—TBXAS1—prostate cancer	8.54e-06	0.000121	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IGF1R—prostate cancer	8.48e-06	0.000121	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—CXCL8—prostate cancer	8.45e-06	0.00012	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—JAK2—prostate cancer	8.4e-06	0.000119	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CG—prostate cancer	8.35e-06	0.000119	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—APC—prostate cancer	8.35e-06	0.000119	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTA2—prostate cancer	8.33e-06	0.000118	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—IL2—prostate cancer	8.25e-06	0.000117	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IRS1—prostate cancer	8.25e-06	0.000117	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—EGF—prostate cancer	8.25e-06	0.000117	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SULT1A1—prostate cancer	8.22e-06	0.000117	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ABCG5—prostate cancer	8.22e-06	0.000117	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TERT—prostate cancer	8.22e-06	0.000117	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—LPL—prostate cancer	8.13e-06	0.000116	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—IL2—prostate cancer	8.07e-06	0.000115	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PDGFRB—prostate cancer	8.06e-06	0.000115	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTA1—prostate cancer	8.03e-06	0.000114	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—GSK3B—prostate cancer	8.01e-06	0.000114	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3CB—prostate cancer	7.98e-06	0.000113	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NAT2—prostate cancer	7.94e-06	0.000113	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTO1—prostate cancer	7.94e-06	0.000113	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HSD3B2—prostate cancer	7.94e-06	0.000113	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—INS—prostate cancer	7.9e-06	0.000112	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—HIF1A—prostate cancer	7.86e-06	0.000112	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ITGB3—prostate cancer	7.86e-06	0.000112	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CREBBP—prostate cancer	7.74e-06	0.00011	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—LEP—prostate cancer	7.68e-06	0.000109	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CXCL8—prostate cancer	7.67e-06	0.000109	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IGF1—prostate cancer	7.64e-06	0.000109	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ERBB3—prostate cancer	7.62e-06	0.000108	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PLCB2—prostate cancer	7.62e-06	0.000108	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP2C18—prostate cancer	7.62e-06	0.000108	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—LRP2—prostate cancer	7.62e-06	0.000108	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—FGFR2—prostate cancer	7.61e-06	0.000108	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CAV1—prostate cancer	7.61e-06	0.000108	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—EGFR—prostate cancer	7.6e-06	0.000108	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—KDR—prostate cancer	7.52e-06	0.000107	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—P4HB—prostate cancer	7.47e-06	0.000106	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MAP2K1—prostate cancer	7.39e-06	0.000105	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CD—prostate cancer	7.34e-06	0.000104	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—IL2—prostate cancer	7.33e-06	0.000104	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ESR1—prostate cancer	7.33e-06	0.000104	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TERT—prostate cancer	7.3e-06	0.000104	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—PIK3CA—prostate cancer	7.27e-06	0.000103	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SLC22A1—prostate cancer	7.27e-06	0.000103	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—SERPINE1—prostate cancer	7.26e-06	0.000103	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—KRAS—prostate cancer	7.18e-06	0.000102	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—BAD—prostate cancer	7.15e-06	0.000102	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SULT2A1—prostate cancer	7.08e-06	0.000101	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—FGF2—prostate cancer	7.03e-06	9.98e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—HIF1A—prostate cancer	6.98e-06	9.92e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—MED12—prostate cancer	6.97e-06	9.89e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—NOS3—prostate cancer	6.93e-06	9.84e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CG—prostate cancer	6.93e-06	9.84e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—APC—prostate cancer	6.93e-06	9.84e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GNG5—prostate cancer	6.91e-06	9.82e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IRS1—prostate cancer	6.85e-06	9.73e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—EGF—prostate cancer	6.85e-06	9.73e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—LEP—prostate cancer	6.82e-06	9.69e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CAV1—prostate cancer	6.76e-06	9.6e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—JAK2—prostate cancer	6.73e-06	9.57e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—KDR—prostate cancer	6.68e-06	9.49e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NCOA3—prostate cancer	6.66e-06	9.46e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—GSK3B—prostate cancer	6.65e-06	9.44e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—PIK3CA—prostate cancer	6.6e-06	9.38e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MDM2—prostate cancer	6.57e-06	9.34e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—INS—prostate cancer	6.56e-06	9.32e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ESR1—prostate cancer	6.51e-06	9.25e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—ERBB2—prostate cancer	6.48e-06	9.21e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CREBBP—prostate cancer	6.42e-06	9.12e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CB—prostate cancer	6.4e-06	9.09e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—BAD—prostate cancer	6.35e-06	9.03e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HPGDS—prostate cancer	6.35e-06	9.02e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IGF1—prostate cancer	6.34e-06	9.01e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—EGFR—prostate cancer	6.31e-06	8.97e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP2C19—prostate cancer	6.31e-06	8.96e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ACHE—prostate cancer	6.16e-06	8.75e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTT1—prostate cancer	6.16e-06	8.75e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CG—prostate cancer	6.15e-06	8.74e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—APC—prostate cancer	6.15e-06	8.74e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CXCL8—prostate cancer	6.15e-06	8.73e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MAP2K1—prostate cancer	6.13e-06	8.71e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CD—prostate cancer	6.09e-06	8.65e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP2A6—prostate cancer	6.09e-06	8.65e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IRS1—prostate cancer	6.08e-06	8.64e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—EGF—prostate cancer	6.08e-06	8.64e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—PIK3CA—prostate cancer	6.03e-06	8.57e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—SERPINE1—prostate cancer	6.02e-06	8.56e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CDKN1B—prostate cancer	6e-06	8.53e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—KRAS—prostate cancer	5.96e-06	8.47e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—AKT1—prostate cancer	5.94e-06	8.43e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—AKR1C3—prostate cancer	5.92e-06	8.41e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—GSK3B—prostate cancer	5.9e-06	8.39e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PRKACB—prostate cancer	5.89e-06	8.37e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CASP3—prostate cancer	5.88e-06	8.36e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IL2—prostate cancer	5.87e-06	8.34e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—IL6—prostate cancer	5.84e-06	8.3e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—FGF2—prostate cancer	5.83e-06	8.28e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP17A1—prostate cancer	5.83e-06	8.28e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—INS—prostate cancer	5.82e-06	8.27e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—NOS3—prostate cancer	5.75e-06	8.17e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CCND1—prostate cancer	5.73e-06	8.13e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CREBBP—prostate cancer	5.71e-06	8.1e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CTNNB1—prostate cancer	5.67e-06	8.06e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IGF1—prostate cancer	5.63e-06	8e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—EGFR—prostate cancer	5.61e-06	7.96e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—JAK2—prostate cancer	5.59e-06	7.94e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MMP9—prostate cancer	5.56e-06	7.9e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NCOA2—prostate cancer	5.56e-06	7.89e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CDKN1A—prostate cancer	5.54e-06	7.87e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PTEN—prostate cancer	5.53e-06	7.85e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PIK3CA—prostate cancer	5.48e-06	7.78e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MDM2—prostate cancer	5.46e-06	7.75e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MAP2K1—prostate cancer	5.45e-06	7.74e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CD—prostate cancer	5.41e-06	7.68e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—AKT1—prostate cancer	5.39e-06	7.66e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ERBB2—prostate cancer	5.38e-06	7.64e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	5.36e-06	7.61e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	5.35e-06	7.6e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CB—prostate cancer	5.31e-06	7.54e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SLC5A5—prostate cancer	5.3e-06	7.53e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	5.3e-06	7.52e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—EP300—prostate cancer	5.27e-06	7.49e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—FGF2—prostate cancer	5.18e-06	7.36e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.18e-06	7.35e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—SRC—prostate cancer	5.13e-06	7.28e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NQO1—prostate cancer	5.12e-06	7.27e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—NOS3—prostate cancer	5.11e-06	7.26e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CXCL8—prostate cancer	5.1e-06	7.25e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—TH—prostate cancer	5.04e-06	7.17e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—VEGFA—prostate cancer	4.99e-06	7.09e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CDKN1B—prostate cancer	4.98e-06	7.08e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—JAK2—prostate cancer	4.96e-06	7.05e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—STAT3—prostate cancer	4.94e-06	7.02e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—AKT1—prostate cancer	4.93e-06	7e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP1B1—prostate cancer	4.91e-06	6.97e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CASP3—prostate cancer	4.88e-06	6.94e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IL2—prostate cancer	4.88e-06	6.93e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	4.87e-06	6.91e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—IL6—prostate cancer	4.85e-06	6.89e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MDM2—prostate cancer	4.85e-06	6.88e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	4.78e-06	6.79e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GGT1—prostate cancer	4.75e-06	6.75e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CCND1—prostate cancer	4.75e-06	6.75e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	4.72e-06	6.7e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	4.71e-06	6.69e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NCOA1—prostate cancer	4.68e-06	6.65e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MMP9—prostate cancer	4.61e-06	6.55e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP19A1—prostate cancer	4.61e-06	6.55e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	4.6e-06	6.53e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MYC—prostate cancer	4.59e-06	6.52e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PTEN—prostate cancer	4.59e-06	6.52e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TGFB1—prostate cancer	4.58e-06	6.51e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	4.53e-06	6.44e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—EGFR—prostate cancer	4.49e-06	6.38e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	4.48e-06	6.36e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—RXRA—prostate cancer	4.45e-06	6.33e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	4.42e-06	6.29e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	4.38e-06	6.22e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—EP300—prostate cancer	4.37e-06	6.21e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CASP3—prostate cancer	4.34e-06	6.16e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IL2—prostate cancer	4.33e-06	6.15e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—IL6—prostate cancer	4.31e-06	6.12e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—COMT—prostate cancer	4.29e-06	6.09e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTP1—prostate cancer	4.27e-06	6.06e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—SRC—prostate cancer	4.25e-06	6.04e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—KRAS—prostate cancer	4.24e-06	6.03e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CCND1—prostate cancer	4.22e-06	6e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ITPR1—prostate cancer	4.2e-06	5.97e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	4.18e-06	5.94e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	4.14e-06	5.89e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—STAT3—prostate cancer	4.1e-06	5.83e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MMP9—prostate cancer	4.1e-06	5.82e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	4.08e-06	5.8e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PTEN—prostate cancer	4.07e-06	5.79e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	3.97e-06	5.65e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—TYMS—prostate cancer	3.97e-06	5.64e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTM1—prostate cancer	3.92e-06	5.57e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	3.9e-06	5.54e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—EP300—prostate cancer	3.89e-06	5.52e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—LPL—prostate cancer	3.85e-06	5.47e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MYC—prostate cancer	3.81e-06	5.42e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	3.8e-06	5.4e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—SRC—prostate cancer	3.78e-06	5.37e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TP53—prostate cancer	3.77e-06	5.36e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—EGFR—prostate cancer	3.73e-06	5.3e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP1A1—prostate cancer	3.72e-06	5.28e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ERCC2—prostate cancer	3.69e-06	5.24e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	3.68e-06	5.23e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—STAT3—prostate cancer	3.64e-06	5.18e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—KRAS—prostate cancer	3.52e-06	5e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—MTHFR—prostate cancer	3.47e-06	4.93e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IL6—prostate cancer	3.45e-06	4.9e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PPARA—prostate cancer	3.4e-06	4.83e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MYC—prostate cancer	3.39e-06	4.81e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	3.38e-06	4.8e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—EGFR—prostate cancer	3.31e-06	4.7e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	3.24e-06	4.6e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CAV1—prostate cancer	3.2e-06	4.54e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—AKT1—prostate cancer	3.19e-06	4.52e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TP53—prostate cancer	3.13e-06	4.45e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—KRAS—prostate cancer	3.13e-06	4.44e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.91e-06	4.14e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	2.87e-06	4.08e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IL6—prostate cancer	2.87e-06	4.07e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TP53—prostate cancer	2.78e-06	3.95e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—INS—prostate cancer	2.76e-06	3.92e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CREBBP—prostate cancer	2.7e-06	3.84e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—AKT1—prostate cancer	2.64e-06	3.76e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.56e-06	3.64e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IL6—prostate cancer	2.55e-06	3.62e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NOS3—prostate cancer	2.42e-06	3.44e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—AKT1—prostate cancer	2.35e-06	3.34e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.23e-06	3.17e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PTGS2—prostate cancer	2.21e-06	3.14e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PTEN—prostate cancer	1.93e-06	2.74e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—EP300—prostate cancer	1.84e-06	2.61e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.36e-06	1.93e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—AKT1—prostate cancer	1.11e-06	1.58e-05	CbGpPWpGaD
